MCID: HRT012
MIFTS: 56

Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Heart Valve Disease

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 12 15 63 17 72
Valvular Heart Disease 12 15
Heart Valve Diseases 43 44
Abnormality of the Heart Valves 6
Valvular Heart Diseases 55
Heart Valve Prolapse 44

Classifications:



External Ids:

Disease Ontology 12 DOID:4079
NCIt 50 C45525
SNOMED-CT 68 368009
UMLS 72 C0018824 C0079485

Summaries for Heart Valve Disease

MedlinePlus : 43 Your heart has four valves. Normally, these valves open to let blood flow through or out of your heart, and then shut to keep it from flowing backward. But sometimes they don't work properly. If they don't, you could have Regurgitation - when blood leaks back through the valve in the wrong direction Mitral valve prolapse - when one of the valves, the mitral valve, has "floppy" flaps and doesn't close tightly. It's one of the most common heart valve conditions. Sometimes it causes regurgitation. Stenosis - when the valve doesn't open enough and blocks blood flow Valve problems can be present at birth or caused by infections, heart attacks, or heart disease or damage. The main sign of heart valve disease is an unusual heartbeat sound called a heart murmur. Your doctor can hear a heart murmur with a stethoscope. But many people have heart murmurs without having a problem. Heart tests can show if you have a heart valve disease. Some valve problems are minor and do not need treatment. Others might require medicine, medical procedures, or surgery to repair or replace the valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and dilated cardiomyopathy, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Heart Valve Disease is SMC1A (Structural Maintenance Of Chromosomes 1A), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Amoebiasis. The drugs Atorvastatin and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

PubMed Health : 63 About heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves. These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Wikipedia : 75 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Related Diseases for Heart Valve Disease

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
# Related Disease Score Top Affiliating Genes
1 rheumatic heart disease 32.9 TGFB1 MYOM2 ACE
2 dilated cardiomyopathy 31.6 TGFB1 NPPB NPPA IL1B CTF1 ACE
3 coronary artery anomaly 31.3 NPPB NPPA ACE
4 arteries, anomalies of 31.3 VWF NPPB IL1B ACE
5 mitral valve disease 31.1 NPPA FBN1 ACE
6 migraine with or without aura 1 31.0 HTR2B HTR2A APOH
7 rheumatic disease 30.9 IL1R1 IL1B APOH
8 aortic valve insufficiency 30.9 NPPB FBN1 ELN ACE
9 sleep apnea 30.8 NPPB IL1B HTR2A ACE
10 central sleep apnea 30.7 NPPB NPPA
11 systemic scleroderma 30.6 TGFB1 FBN1 ACE
12 lung disease 30.5 TGFB1 NPPB IL1B ELN
13 coronary stenosis 30.5 VWF NPPB ACE
14 diastolic heart failure 30.5 NPPB NPPA ACE
15 mitral valve insufficiency 30.5 PDLIM1 NPPB NPPA FBN1 ACE
16 congestive heart failure 30.4 NR3C2 NPPB NPPA ACE
17 pulmonary hypertension 30.4 VWF NPPB NPPA HTR2B ACE
18 pulmonary hypertension, primary, 1 30.4 NPPB NPPA FBN1
19 pulmonary embolism 30.3 VWF NPPB APOH
20 acute myocardial infarction 30.3 VWF NPPB NPPA ACE
21 stroke, ischemic 30.2 VWF FBN1 APOH ACE
22 orthostatic intolerance 30.2 PDLIM1 FBN1 ELN
23 pulmonary edema 30.2 NPPB NPPA IL1B ACE
24 vascular disease 30.2 VWF ELN APOH ACE
25 connective tissue disease 30.0 FBN1 ELN APOH ACE
26 kidney disease 29.9 TGFB1 NR3C2 NPPB NPPA ACE
27 atrial fibrillation 29.9 VWF NPPB NPPA ACE
28 heart disease 29.6 VWF NPPB NPPA IL1B ELN ACE
29 aortic valve disease 1 29.6 VWF TGFB1 PDLIM1 NPPB FBN1 ELN
30 aortic valve disease 2 29.2 VWF PDLIM1 NPPB NPPA ELN CNMD
31 disproportionate short stature with ptosis and valvular heart lesions 11.7
32 cardiac valvular dysplasia, x-linked 11.7
33 tricuspid valve stenosis 11.5
34 cardiac valvular defect, developmental 11.3
35 andersen cardiodysrhythmic periodic paralysis 11.2
36 cardiomyopathy, familial hypertrophic, 21 11.2
37 coumarin resistance 11.1
38 tricuspid valve disease 11.1
39 sick sinus syndrome 11.1
40 familial vesicoureteral reflux 10.7 TGFB1 ACE
41 vulvar vestibulitis syndrome 10.7 IL1R1 IL1B
42 late-onset focal dermal elastosis 10.6 FBN1 ELN
43 pseudoxanthoma elasticum-like papillary dermal elastolysis 10.6 FBN1 ELN
44 chronic fatigue syndrome 10.6 TGFB1 IL1B HTR2A
45 hyperlipoproteinemia, type iii 10.6
46 familial abdominal aortic aneurysm 10.6 FBN1 ELN
47 autoimmune atherosclerosis 10.6 APOH ACE
48 hepatoportal sclerosis 10.6 ELN ACE
49 familial cold autoinflammatory syndrome 1 10.6 IL1R1 IL1B
50 hypoaldosteronism 10.6 NPPA ACE

Graphical network of the top 20 diseases related to Heart Valve Disease:



Diseases related to Heart Valve Disease

Symptoms & Phenotypes for Heart Valve Disease

UMLS symptoms related to Heart Valve Disease:


angina pectoris, edema, chest pain, undiagnosed heart murmur

MGI Mouse Phenotypes related to Heart Valve Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 ACE FBN1 HTR2B IL1B IL1R1 NPPA
2 hematopoietic system MP:0005397 9.9 ACE CNMD FBN1 IL1B IL1R1 NPPA
3 adipose tissue MP:0005375 9.8 ACE CTF1 FBN1 HTR2B IL1R1 TGFB1
4 homeostasis/metabolism MP:0005376 9.73 ACE APOH CNMD CTF1 FBN1 IL1B
5 muscle MP:0005369 9.17 FBN1 HTR2A HTR2B IL1R1 NPPA NR3C2

Drugs & Therapeutics for Heart Valve Disease

PubMed Health treatment related to Heart Valve Disease: 63

Currently, no medicines can cure heart valve disease. However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve. The goals of treating heart valve disease might include: Preventing, treating, or relieving the symptoms of other related heart conditions.Protecting heart valves from further damage.Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Remifentanil Approved Phase 4 132875-61-7 60815
3
tannic acid Approved Phase 4 1401-55-4
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Etomidate Approved Phase 4 33125-97-2 36339 667484
9
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
10
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
16
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
17
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
18
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
19
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
20
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
21
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
22
Methyltestosterone Approved Phase 4 58-18-4 6010
23
Testosterone enanthate Approved Phase 4 315-37-7 9416
24
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
25
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
26
Insulin Lispro Approved Phase 4 133107-64-9
27
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
28
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
29
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
Warfarin Approved Phase 4 81-81-2 6691 54678486
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
34
Ticagrelor Approved Phase 4 274693-27-5 9871419
35
Ramipril Approved Phase 4 87333-19-5 5362129
36
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
37
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
38
Hydralazine Approved Phase 4 86-54-4 3637
39
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
40
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
44
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
46 Simendan Investigational Phase 4 131741-08-7
47
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
48 Tocotrienol Investigational Phase 4 6829-55-6
49
Candesartan Experimental Phase 4 139481-59-7 2541
50
Dabigatran Investigational Phase 4 211914-51-1

Interventional clinical trials:

(show top 50) (show all 478)
# Name Status NCT ID Phase Drugs
1 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
2 The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery Unknown status NCT01623193 Phase 4
3 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
4 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
5 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
6 Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%;volume replacement
7 The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
8 Sildenafil for Improving Outcomes After Valvular Correction Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
9 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial Completed NCT01384643 Phase 4 Propofol
10 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting Completed NCT01210976 Phase 4 levosimendan;placebo
11 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
12 Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass Completed NCT02136979 Phase 4 Propofol;Sevoflurane
13 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
14 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
15 A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
16 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
17 The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. Completed NCT01495949 Phase 4 etomidate;thiopentone
18 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
19 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial. Completed NCT01477151 Phase 4 Volatile anesthetic
20 Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation Completed NCT00643188 Phase 4
21 Acute Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus Completed NCT02962921 Phase 4 Insulin LISPRO intravenous loading
22 Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF) Completed NCT02827500 Phase 4 ivabradine
23 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
24 Comparison of Conscious Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Using the Transfemoral Approach: Randomized Double Blind Prospective Study Recruiting NCT03747432 Phase 4 Propofol;Dexmedetomidine
25 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
26 Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction - the ILO-HOPE Clinical Trial Recruiting NCT03620526 Phase 4 Iloprost;Placebo
27 Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation Active, not recruiting NCT02247128 Phase 4 Aspirin + clopidogrel;Aspirin monotherapy;OAC + clopicogrel;OAC monotherapy
28 Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery Active, not recruiting NCT03280745 Phase 4 Hypertonic saline;0.9% saline
29 Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC) Active, not recruiting NCT00512759 Phase 4 Goal-directed preload and afterload decrement
30 Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial Not yet recruiting NCT04045093 Phase 4 Dabigatran etexilate;Warfarin
31 Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement Not yet recruiting NCT03440268 Phase 4 N Acetyl Cysteine;Placebos
32 Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy Suspended NCT01536717 Phase 4 Articaine hydrochloride 2% solution;Sodium Chloride
33 Effects of Continuous Positive Airway Pressure on Heart Remodeling in Patients With Obstructive Sleep Apnea: A Randomized Study With Cardiovascular Magnetic Resonance Imaging Terminated NCT00727454 Phase 4
34 Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial Withdrawn NCT00187304 Phase 4
35 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
36 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
37 Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial Unknown status NCT01478984 Phase 3
38 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
39 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
40 Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair Completed NCT02084069 Phase 3 Atorvastatin
41 Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial Completed NCT02833948 Phase 3 Acetylicsalicylic acid;Clopidogrel;Rivaroxaban
42 Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery Completed NCT02237495 Phase 2, Phase 3 dexmedetomidine;placebo
43 A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol Completed NCT02098772 Phase 3 Custodiol-N;Custodiol
44 Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study) Completed NCT01202721 Phase 3 Atenolol;Telmisartan
45 Studies of Left Ventricular Dysfunction (SOLVD) Completed NCT00000516 Phase 3 enalapril
46 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
47 Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Recruiting NCT03566303 Phase 2, Phase 3 Rivaroxaban 15 mg;Warfarin
48 RIvoraxaban Safety and Efficacy in Patients With Mitral Stenosis Recruiting NCT03926156 Phase 3 Rivaroxaban;Warfarin
49 INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies Recruiting NCT02832544 Phase 3 Rivaroxaban (20 mg);Vitamin K antagonists (VKA)
50 Mandibular Advancement Device for Treatment of Obstructive Sleep Apnea and Its Impact on Cardiac Remodeling Recruiting NCT02948894 Phase 2, Phase 3

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Genetic Tests for Heart Valve Disease

Anatomical Context for Heart Valve Disease

MalaCards organs/tissues related to Heart Valve Disease:

41
Heart, Testes, Lung, Kidney, Liver, Brain, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease

Publications for Heart Valve Disease

Articles related to Heart Valve Disease:

(show top 50) (show all 5514)
# Title Authors PMID Year
1
The MITRA-HR study: design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery. 17
30987963 2019
2
Transcatheter aortic valve replacement. 17
31124850 2019
3
Why should we extend transcatheter aortic valve implantation to low-risk patients? A comprehensive review. 17
31014990 2019
4
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 9 38
20436747 2010
5
Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? 9 38
18307738 2008
6
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 9 38
17345160 2007
7
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]. 9 38
16029597 2005
8
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 9 38
16043943 2005
9
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. 9 38
15721858 2005
10
Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. 9 38
14973795 2004
11
Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. 9 38
14674704 2003
12
Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. 9 38
14677016 2003
13
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. 9 38
14608520 2003
14
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. 9 38
12761331 2003
15
Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. 9 38
12630582 2003
16
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. 9 38
12466135 2002
17
Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. 9 38
12270761 2002
18
Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. 9 38
9286500 1997
19
Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. 9 38
9104915 1997
20
Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis. 9 38
8467615 1993
21
Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. 9 38
8451600 1993
22
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 9 38
1611635 1992
23
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 9 38
1933972 1991
24
Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus. 9 38
1975008 1990
25
Risk of cardiac arrhythmias in patients with chronic hepatitis B and C infections - A 13-year nationwide population-based study. 38
30982681 2019
26
Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. 38
31171392 2019
27
Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. 38
31203254 2019
28
Transport of Critically Ill Patients by the Anesthesia Versus the Intensive Care Unit Service: A Before-After Study of Operating Room Workflows. 38
31425206 2019
29
Minimally Invasive Surgical Options with Valvular Heart Disease. 38
31351549 2019
30
Contemporary Imaging of Aortic Stenosis. 38
31266725 2019
31
Cardiac Computed Tomography - More Than Coronary Arteries? A Clinical Update. 38
31250415 2019
32
Serial Changes in Left Ventricular Ejection Fraction and Outcomes in Outpatients With Heart Failure and Preserved Ejection Fraction. 38
31272702 2019
33
Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. 38
31408153 2019
34
Possibility of Cardio-renal Protection by Long-term Cardiac Rehabilitation in Elderly Patients with Cardiovascular Diseases. 38
30996165 2019
35
Incremental direct healthcare expenditures of valvular heart disease in the USA. 38
31433207 2019
36
Lung Ultrasound During Stress Echocardiography Aids the Evaluation of Valvular Heart Disease Severity. 38
31422148 2019
37
Comparative Accuracy of Focused Cardiac Ultrasonography and Clinical Examination for Left Ventricular Dysfunction and Valvular Heart Disease: A Systematic Review and Meta-analysis. 38
31382273 2019
38
Quantitative proteomics of changes in succinylated proteins expression profiling in left appendages tissue from valvular heart disease patients with atrial fibrillation. 38
31059701 2019
39
The protective effects of L-carnitine on myocardial ischemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery are associated with the suppression of NF-κB pathway and the activation of Nrf2 pathway. 38
31393619 2019
40
"A Tale of Two Cities": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants. 38
31382702 2019
41
Bridging gaps in heart valve disease care: Opportunities for quality improvement. 38
31237112 2019
42
Heart Valve Disease Predict Mortality in Hemodialysis Patients: A Single Center Experience. 38
30421548 2019
43
MicroRNA-638 inhibits human aortic valve interstitial cell calcification by targeting Sp7. 38
31140727 2019
44
Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry. 38
31171564 2019
45
Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. 38
31129607 2019
46
Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). 38
31374021 2019
47
Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. 38
31389986 2019
48
Safety and efficacy of hybrid vascular closure technique using both a suture- and collagen-mediated closure device after transfemoral transcatheter aortic valve implantation. 38
31379116 2019
49
ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. 38
31250324 2019
50
Echocardiographic evaluation of left ventricular strain in severe aortic stenosis with therapeutic implications and risk stratification. 38
31414735 2019

Variations for Heart Valve Disease

ClinVar genetic disease variations for Heart Valve Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SMC1A NM_006306.3(SMC1A): c.796_798AAG[2] (p.Lys268del) short repeat Pathogenic rs727503773 X:53439900-53439902 X:53412950-53412952

Expression for Heart Valve Disease

Search GEO for disease gene expression data for Heart Valve Disease.

Pathways for Heart Valve Disease

GO Terms for Heart Valve Disease

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TGFB1 NPPB NPPA MIR205 IL1B FBN1
2 extracellular matrix GO:0031012 9.43 TGFB1 FBN1 ELN
3 collagen-containing extracellular matrix GO:0062023 9.43 VWF TGFB1 NPPA FBN1 ELN APOH
4 extracellular region GO:0005576 9.4 VWF TGFB1 NPPB NPPA IL1R1 IL1B

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 TGFB1 IL1B HTR2B HTR2A CTF1
2 cytokine-mediated signaling pathway GO:0019221 9.88 TGFB1 IL1R1 IL1B CTF1
3 response to drug GO:0042493 9.77 TGFB1 HTR2B HTR2A
4 cellular calcium ion homeostasis GO:0006874 9.74 TGFB1 HTR2B HTR2A
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 TGFB1 HTR2B HTR2A
6 cellular response to mechanical stimulus GO:0071260 9.67 TGFB1 NPPA IL1B
7 positive regulation of histone acetylation GO:0035066 9.61 TGFB1 IL1B
8 regulation of blood vessel size GO:0050880 9.59 NPPB NPPA
9 blood coagulation, intrinsic pathway GO:0007597 9.58 VWF APOH
10 regulation of blood pressure GO:0008217 9.58 NPPB NPPA ACE
11 regulation of blood vessel diameter GO:0097746 9.55 NPPB ACE
12 positive regulation of MAP kinase activity GO:0043406 9.54 TGFB1 HTR2B HTR2A
13 receptor guanylyl cyclase signaling pathway GO:0007168 9.52 NPPB NPPA
14 cGMP biosynthetic process GO:0006182 9.51 NPPB NPPA
15 response to hypoxia GO:0001666 9.5 TGFB1 PDLIM1 NPPA
16 serotonin receptor signaling pathway GO:0007210 9.48 HTR2B HTR2A
17 cellular response to insulin-like growth factor stimulus GO:1990314 9.46 TGFB1 FBN1
18 behavior GO:0007610 9.43 HTR2B HTR2A
19 positive regulation of cell division GO:0051781 9.33 TGFB1 IL1B HTR2B
20 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.26 IL1R1 IL1B
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 8.96 HTR2B HTR2A
22 mononuclear cell proliferation GO:0032943 8.62 TGFB1 ACE

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 NPPB NPPA FBN1
2 drug binding GO:0008144 9.33 HTR2B HTR2A ACE
3 serotonin binding GO:0051378 9.26 HTR2B HTR2A
4 extracellular matrix constituent conferring elasticity GO:0030023 8.96 FBN1 ELN
5 hormone receptor binding GO:0051427 8.62 NPPB NPPA

Sources for Heart Valve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....